Alpha 2.0
Login Register
» Articles » PMID: 36810791

XBB.1.5 Neutralizing Antibodies Upon Bivalent COVID-19 Vaccination Are Similar to XBB but Lower Than BQ.1.1

Overview
Journal Am J Hematol
Specialty Hematology
Date 2023 Feb 22
PMID 36810791
Authors
Santhi Devasundaram
Evangelos Terpos
Margherita Rosati
Ioannis Ntanasis-Stathopoulos
Jenifer Bear
Robert Burns
Stamatia Skourti
Panagiotis Malandrakis
Ioannis P Trougakos
Meletios-Athanasios Dimopoulos
George N Pavlakis
Barbara K Felber
Affiliations
Soon will be listed here.
Citing Articles

Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in People Living with HIV (PLWH).

Cherneha M, Zydek I, Brass P, Korth J, Jansen S, Esser S Vaccines (Basel). 2024; 12(7).

PMID: 39066423 PMC: 11281445. DOI: 10.3390/vaccines12070785.

Diminished neutralizing activity against the XBB1.5 strain in 55.9% of individuals post 6 months COVID-19 mRNA booster vaccination: insights from a pseudovirus assay on 1,353 participants in the Fukushima vaccination community survey, Japan.

Zhao T, Tani Y, Makino-Okamura C, Takita M, Yamamoto C, Kawahara E Front Immunol. 2024; 15:1337520.

PMID: 38562937 PMC: 10983612. DOI: 10.3389/fimmu.2024.1337520.

Prefusion-stabilized SARS-CoV-2 S2-only antigen provides protection against SARS-CoV-2 challenge.

Hsieh C, Leist S, Miller E, Zhou L, Powers J, Tse A Nat Commun. 2024; 15(1):1553.

PMID: 38378768 PMC: 10879192. DOI: 10.1038/s41467-024-45404-x.

Rapid transient and longer-lasting innate cytokine changes associated with adaptive immunity after repeated SARS-CoV-2 BNT162b2 mRNA vaccinations.

Rosati M, Terpos E, Homan P, Bergamaschi C, Karaliota S, Ntanasis-Stathopoulos I Front Immunol. 2023; 14:1292568.

PMID: 38090597 PMC: 10711274. DOI: 10.3389/fimmu.2023.1292568.

Analysis of the protective efficacy of approved COVID-19 vaccines against Omicron variants and the prospects for universal vaccines.

Chen K, Zhang L, Fang Z, Li J, Li C, Song W Front Immunol. 2023; 14:1294288.

PMID: 38090587 PMC: 10711607. DOI: 10.3389/fimmu.2023.1294288.

References
1.
Davis-Gardner M, Lai L, Wali B, Samaha H, Solis D, Lee M . Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster. N Engl J Med. 2022; 388(2):183-185. PMC: 9812288. DOI: 10.1056/NEJMc2214293. View
2.
Wang Q, Iketani S, Li Z, Liu L, Guo Y, Huang Y . Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell. 2022; 186(2):279-286.e8. PMC: 9747694. DOI: 10.1016/j.cell.2022.12.018. View
3.
Cao Y, Yisimayi A, Jian F, Song W, Xiao T, Wang L . BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature. 2022; 608(7923):593-602. PMC: 9385493. DOI: 10.1038/s41586-022-04980-y. View
4.
Uraki R, Ito M, Furusawa Y, Yamayoshi S, Iwatsuki-Horimoto K, Adachi E . Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB. Lancet Infect Dis. 2022; 23(1):30-32. PMC: 9729000. DOI: 10.1016/S1473-3099(22)00816-7. View
5.
Arora P, Cossmann A, Schulz S, Ramos G, Stankov M, Jack H . Neutralisation sensitivity of the SARS-CoV-2 XBB.1 lineage. Lancet Infect Dis. 2023; 23(2):147-148. PMC: 9815825. DOI: 10.1016/S1473-3099(22)00831-3. View